Liang Pu, Yu Liqian, Xia Bowen, Zhang Dongxu
Beijing Key Laboratory of Emerging Infectious Diseases, Institute of Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; Beijing Institute of Infectious Diseases, Beijing, China; National Center for Infectious Diseases, Beijing Ditan Hospital, Capital Medical University, Beijing, China; National Key Laboratory of Intelligent Tracking and Forecasting for Infectious Diseases, Beijing, China.
Qingdao University Medical College, Qingdao, China.
Urology. 2025 May;199:182-190. doi: 10.1016/j.urology.2025.02.018. Epub 2025 Feb 17.
To compare the efficacy and safety of mirabegron and vibegron in female patients with overactive bladder (OAB).
This study followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. A meta-analysis of randomized controlled trials (RCTs) referred to the use of mirabegron and vibegron in female patients with OAB from PubMed, EMBASE, Cochrane Library, and Web of Science databases was performed.
Three RCTs involving 371 patients were included. We found that vibegron was more effective in relieving urgency urinary incontinence in females with OAB compared to mirabegron [mean difference (MD)=0.25, 95% confidence interval (CI) 0.04 to 0.47, p=0.02]. And vibegron was similar to mirabegron in OAB symptom score (OABSS) [MD=0.22, 95% CI -0.32 to 0.76, p=0.42], urgency (MD=0.15, 95% CI -0.08 to 0.38, p=0.20), quality of life (QOL) (MD=-0.18, 95% CI -0.49 to 0.13, p=0.26), mean volume voided per micturition (MD=-6.16, 95% CI -21.50 to -9.17, p=0.43). In terms of the safety outcomes, there were no significant differences between mirabegron and control groups in terms of the total adverse events (TAEs) [odds ratio (OR)=0.75; 95% CI: 0.44 to 1.26; p=0.28], dry mouth (OR=1.01; 95% CI: 0.36 to 2.81; p=0.99), constipation (OR=0.69; 95% CI: 0.33 to 1.44; p=0.32), elevated post-void residual (PVR) (OR=0.35; 95% CI: 0.05 to 2.23; p=0.26), and dizziness (OR=1.02; 95% CI: 0.14 to 7.31; p=0.98).
In female OAB patients, the efficacy and safety of mirabegron and vibegron were similar. Vibegron may be more effective than mirabegron in relieving urgency urinary incontinence.
比较米拉贝隆和维贝隆治疗女性膀胱过度活动症（OAB）的疗效和安全性。
本研究遵循系统评价和Meta分析的首选报告项目（PRISMA）指南。对来自PubMed、EMBASE、Cochrane图书馆和科学网数据库中有关米拉贝隆和维贝隆用于女性OAB患者的随机对照试验（RCT）进行Meta分析。
纳入3项涉及371例患者的RCT。我们发现，与米拉贝隆相比，维贝隆在缓解女性OAB患者的急迫性尿失禁方面更有效[平均差（MD）=0.25，95%置信区间（CI）0.04至0.47，p=0.02]。在OAB症状评分（OABSS）方面，维贝隆与米拉贝隆相似[MD=0.22，95%CI -0.32至0.76，p=0.42]，在尿急方面[MD=0.15，95%CI -0.08至0.38，p=0.20]，生活质量（QOL）方面[MD=-0.18，95%CI -0.49至0.13，p=0.26]，每次排尿平均尿量[MD=-6.16，95%CI -21.50至-9.17，p=0.43]。在安全性结果方面，米拉贝隆组与对照组在总不良事件（TAEs）[比值比（OR）=0.75；95%CI：0.44至1.26；p=0.28]、口干（OR=1.01；95%CI：0.36至2.81；p=0.99）、便秘（OR=0.69；95%CI：0.33至1.44；p=0.32）、残余尿量（PVR）升高（OR=0.35；95%CI：0.05至2.23；p=0.26）和头晕（OR=1.02；95%CI：0.14至7.31；p=0.98）方面无显著差异。
在女性OAB患者中，米拉贝隆和维贝隆的疗效和安全性相似。维贝隆在缓解急迫性尿失禁方面可能比米拉贝隆更有效。
